Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : VYNE Therapeutics Inc.

Consensus VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-11-27 pm EST 		Intraday chart for VYNE Therapeutics Inc. 5-day change 1st Jan Change
3.970 USD -1.00% +0.51% +47.04%
Nov. 13 Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 MT
Nov. 13 VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Evolution of the average Target Price on VYNE Therapeutics Inc.

Price target over the last 5 years

History : Analyst Recommendations

71b4f09992339f0c524906b4cbc75.HA95K2HqjKEl3mvMKHjv_fw3tY163i8NHg4GDtWO8aA.eG4QTiraxZRp6ib1RgG-i6ZCxNw5jUJMUVZePr_ewcVXQh5RUZzkmG21Ig~61c4b7834a24a28fbbafc3478b9e097d

Analyst Recommendations on VYNE Therapeutics Inc.

Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating MT
HC Wainwright Cuts VYNE Therapeutics' Price Target to $1.50 From $7, Maintains Buy Rating MT
HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target MT
VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keeps Outperform Rating MT
VYNE THERAPEUTICS : HC Wainwright Adjusts VYNE Therapeutics' Price Target to $11 from $14, Keeps Buy Rating MT
VYNE THERAPEUTICS : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.970USD
Average target price
5.583USD
Spread / Average Target
+40.64%
High Price Target
6.000USD
Spread / Highest target
+51.13%
Low Price Target
5.000USD
Spread / Lowest Target
+25.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering VYNE Therapeutics Inc.

Cantor Fitzgerald
HC Wainwright
Northland Securities

Ratings for VYNE Therapeutics Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock
  2. Equities
  3. Stock VYNE Therapeutics Inc. - Nasdaq
  4. Consensus VYNE Therapeutics Inc.
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer